MQS Management LLC Invests $288,000 in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

MQS Management LLC bought a new position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) during the 1st quarter, HoldingsChannel reports. The fund bought 2,394 shares of the specialty pharmaceutical company’s stock, valued at approximately $288,000.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. raised its position in Jazz Pharmaceuticals by 1.3% in the first quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock valued at $776,551,000 after purchasing an additional 84,941 shares during the period. LSV Asset Management boosted its stake in Jazz Pharmaceuticals by 1.6% in the first quarter. LSV Asset Management now owns 2,380,858 shares of the specialty pharmaceutical company’s stock valued at $286,703,000 after acquiring an additional 37,631 shares in the last quarter. Polaris Capital Management LLC boosted its stake in Jazz Pharmaceuticals by 13.0% in the first quarter. Polaris Capital Management LLC now owns 1,432,660 shares of the specialty pharmaceutical company’s stock valued at $172,521,000 after acquiring an additional 165,200 shares in the last quarter. Baupost Group LLC MA boosted its stake in Jazz Pharmaceuticals by 23.7% in the fourth quarter. Baupost Group LLC MA now owns 833,696 shares of the specialty pharmaceutical company’s stock valued at $102,545,000 after acquiring an additional 160,000 shares in the last quarter. Finally, Vestal Point Capital LP acquired a new position in Jazz Pharmaceuticals in the fourth quarter valued at $89,175,000. 89.14% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on JAZZ shares. StockNews.com cut shares of Jazz Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, July 5th. Morgan Stanley reduced their price objective on shares of Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a research report on Friday, July 12th. Cantor Fitzgerald restated an “overweight” rating and issued a $180.00 price objective on shares of Jazz Pharmaceuticals in a research report on Wednesday, April 10th. Needham & Company LLC reduced their price objective on shares of Jazz Pharmaceuticals from $222.00 to $210.00 and set a “buy” rating for the company in a research report on Thursday, June 20th. Finally, The Goldman Sachs Group assumed coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 5th. They set a “buy” rating and a $169.00 price target for the company. Three research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $185.86.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ traded up $1.66 during mid-day trading on Friday, reaching $111.20. 115,805 shares of the company’s stock were exchanged, compared to its average volume of 670,059. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 1.38. The company has a 50-day simple moving average of $107.17 and a two-hundred day simple moving average of $114.48. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $146.70. The company has a market cap of $7.01 billion, a price-to-earnings ratio of 22.59, a PEG ratio of 1.67 and a beta of 0.58.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its earnings results on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 EPS for the quarter, missing the consensus estimate of $3.53 by ($1.55). The firm had revenue of $901.98 million during the quarter, compared to analysts’ expectations of $938.99 million. Jazz Pharmaceuticals had a return on equity of 27.86% and a net margin of 8.61%. On average, sell-side analysts predict that Jazz Pharmaceuticals plc will post 15.32 EPS for the current fiscal year.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 5,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $109.65, for a total value of $548,250.00. Following the completion of the sale, the executive vice president now directly owns 36,629 shares of the company’s stock, valued at approximately $4,016,369.85. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.